Christopher Robart leads Ambyint — a technology company creating the Nest thermostat for oil rigs — with his twin brother, Alex. Courtesy of Ambyint

Most of Christopher Robart's 10-year career in oil and gas has been deliberate and calculated — researching the right startup to be involved in or finding the right buyer for a company he invested in. However, his actual start in the industry wasn't so intentional.

"I sort of fell into oil and gas after I got of college back in 2003," says Robart, who is the president of Ambyint USA. "Before that, I was involved in a few startup things — some digital and some not. I was always sort of an entrepreneur."

Robart shares the passion of entrepreneurialism with his twin brother, Alex, CEO of Ambyint. The two have similar work experiences, since they act as an oil and gas startup team in Houston. One of the first companies the duo bought and sold was PacWest Consulting Partners, which was sold to IHS Energy in 2014, Robart says. The second one, Digital H2O, they founded, grew the team, lead some investments, and sold it to Genscape in 2015.

The pair's newest endeavor is Ambyint, an oilfield smart technology company with Canadian origins. The Robart brothers have been involved in it for about two and a half years.

Christopher Robart spoke with InnovationMap about his career and what he hopes to accomplish with his oil and gas startup in 2019.

InnovationMap: How did you and your brother first get involved in Ambyint?

Christopher Robart: After we left IHS, we knew that our next up was going to be software and upstream oil and gas, but there were a lot of question marks. We did our due diligence. We leveraged all that information we found and settled on which market we wanted to be in. We ended up finding Ambyint and liked what they had built to date, but they had some gaps and shortcomings, particularly on the commercial side, and they had no U.S. presence. We thought those two gaps were something we'd be helpful filling out. We went through a fairly lengthy process to lead an investment into the company, and essentially took over through that process.

IM: So, Ambyint still has an office in Canada?

CR: The Canada office is primarily a technology office, with some sales capabilities up there. The U.S. is primarily sales, marketing, and customer support.

IM: How does the technology work?

CR: The easiest way to explain it is we're like a Nest thermostat for your oil wells. It's a piece of hardware and a piece of software. It's wired into the well's control system and tied up to cloud-based software. From there, we've been deploying artificial intelligence, machine learning, deep learning, etc.

IM: What do you look for in customers?

CR: Oil companies of any shape or size, really. Oil and gas industry aren't really known for being early adopters of technology. There's a lot of resistance to change, particularly at the production level, which we focus on. So we're looking for early adopters looking to lead the way.

We're in pretty much all the major oil-producing areas in the U.S. and Canada. We also have customers in Mexico, Chili, and Egypt. There's a few more countries in the Middle East we're trying to get into.

IM: Are you planning another fundraising round?

CR: We'll embark on a series B in the near future. We closed our series A, and it was pretty large, so we're in a good place. (The series closed in September of 2017 with $11.5 million raised, according to Crunchbase.)

IM: What are your goals for 2019?

CR: We've built a lot of cool technology, and we continue to do that. Our focus for 2019 is to continue to commercialize and expand our customer base. Our sales cycle is pretty long. It could be a year from the time we bring an initial lead to the table, running a pilot, getting results, and developing a plan. It's a long, slow, and, in some cases, a painful process.

When you're doing things like machine learning, you're teaching a machine how to do something a human would do something. What's required to do that is a massive amount of data to start, and from there, it's a never ending journey of data collection and monitoring your accuracy.

We've been focused on one specific artificial lift pump — every well will eventually take a piece of artificial lift pump. We work on the most common artificial lift pump, but it's just one of six key types. In addition to selling more of that pump, we are in the process of expanding to additional lift types.

IM: What keeps you up at night, as it pertains to your business?

CR: Change management. Getting our customers to adopt new technology and embrace change. That's it. We're constantly trying to get our customers to move more quickly.

IM: How do you and your brother work together? Do you each play different roles in the company?

CR: Our backgrounds are similar. We're twins, but we have personality differences. I spend a little more time with our customers than he does and with new product initiatives. I get pretty hands on.

His mandate is less focused on walking and talking with customers and more on managing the functions of the business and working with the leadership team. As well as financing and fundraising.

We've got a pretty good division of labor, but there is a lot of overlap of what we do.

IM: What are some of the pros and cons of being in Houston?

CR: Obviously the pro of being in Houston is it being the oil capital of the world. All our customers are here. It's sort of a must.

The downside of running a technology company in town is that tech talent is quite thin on the ground in Houston — especially what we're looking for. So, we don't have any tech team members in the Houston office. I'll put it mildly in that we are skeptical of the talent pool for really strong software developers in the Houston market.

------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

Houston energy hub opens new fundraising cohort to fuel startups

Apply Now

EnergyTech Cypher has opened applications for its second Liftoff fundraising program.

Applications close May 20 for the 10-week virtual fundraising sprint. The program is geared toward energy and climatech founders preparing to raise their first institutional round. It will cover fundraising requisites, like pitch materials, term sheet negotiation and round closing, according to a release from EnergyTech Cypher.

The program kicks off June 1 and runs every Monday from 1-3 p.m. CST. It will conclude with an in-person capstone simulation in Houston on August 3, where founders will work to close a mock round.

Jason Ethier, EnergyTech Cypher founder and CEO, will lead the program with Payal Patel, an EnergyTech fellow and entrepreneur in residence.

The program is available through Cephyron, EnergyTech Cypher's new investor relationship management platform, built specifically for energy and climatech founders. Users must have a Cephyron Boost membership to participate in the Liftoff program.

The Cephyron IRM app recently went live and is available to founders at any point in their fundraising process, according to the news release. The platform aggregates investor data, tracks market signals and delivers curated weekly recommendations.

EnergyTech Cypher launched Liftoff last year. The inaugural cohort included 19 startups, including Houston-based AtmoSpark Technologies, The Woodlands-based Resollant and others. Each participant closed at least one fundraising deal, according to EnergyTech Cypher.

EnergyTech Cypher rebranded from EnergyTech Nexus earlier this year. It also launched its CoPilot accelerator in 2025. The inaugural group presented its first showcase during CERAWeek last month.

EnergyTech Cypher's annual Pilotathon Pilot Pitch and Showcase applications also opened this month. Find more information here.

---

This article originally appeared on EnergyCaptialHTX.com.

Cancer diagnostics startup wins top prize at annual Rice competition​

winner, winners

Rice University student-founded companies took home a total of $115,000 in equity-free funding at the annual Liu Idea Lab for Innovation and Entrepreneurship's H. Albert Napier Rice Launch Challenge last week.

2025 Rice Innovation Fellow Alexandria Carter won the top prize and $50,000 for her startup Bionostic. The startup offers personalized diagnostics for cancer patients by using 3D culturing through its Advanced Tumor Landscape Analysis System (ATLAS) platform.

Carter is working toward her PhD in bioengineering in Professor Michael King's laboratory. She recently completed the Rice Innovation Fellows program and plans to commercialize ATLAS, according to a news release from Rice.

Actile Technologies, founded by another former Rice Innovation Fellow, Barclay Jumet, won second place and $25,000. The company is developing and commercializing textile-integrated technologies. InnovationMap first covered Jumet's wearable technology back in 2023.

Kairos took home the third-place prize and $15,000, plus the $2,000 audience choice award and the $5,000 undergraduate business award. Founded last year by Sanjana Kavula and Adhira Tippur, Kairos is an AI-powered patient intake platform built specifically for independent dental practices.

The NRLC features top startups founded by undergraduate, graduate and MBA students at Rice each year. The top three finishers were named among a group of five finalists earlier this year, which also included HAAST Autonomous and Project Kestrel.

HAAST is developing an unmanned aircraft for organ transport, while Kestrel uses machine learning to organize bird photographers’ photo collections.

Teams presented multiple five-minute pitches throughout the application process over Zoom and in-person before the five finalists presented at the NRLC Championships April 21 at the Rice Memorial Center. Each finalist walked away with an equity-free investment.


Other awards went to:

UnitCode

  • $5,000 MBA Venture Award

HAAST Autonomous

  • $2,500 Chan-Kang Family Prize for Bold Ambition
  • $1,000 Healthcare Innovations Prize

Telstar Networks

  • $2,500 Outstanding Undergraduate Startup Award

Multiplay

  • $1,500 Frank Liu Jr. Prize for Creative Innovation in Music, Fashion, & the Arts

Butterfly Books

  • $1,500 Social Impact Award

SOOZ

  • $1,000 Interdisciplinary Innovation Prize sponsored by OURI

Dooly

  • $1,000 Consumer Goods Prize

Project Kestrel

  • $1,000 AI Prize

Veloci Running won the NRLC last year for its naturally shaped running shoe. Founder and CEO Tyler Strothman recently told InnovationMap that the company has gone on to sell roughly 10,000 pairs of its flagship Ascent shoe, designed to relieve lower leg tightness and absorb impact. Read more here.